Opinion statement
Aortic stenosis is the most important valvular heart disease affecting the elderly population. Surgical aortic valve replacement is the mainstay of treatment, although a substantial number of patients are considered high risk for surgery. Many of these patients do not undergo surgery and have poor outcomes from medically treated symptomatic, severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) provides a promising treatment option for some of these patients. Several devices are under investigation. The Edwards Sapien valve (Edwards Lifesciences, Irvine, CA) and the CoreValve (Medtronic, Minneapolis, MN) have the largest human experience to date. Initial data suggest that these devices have an acceptable safety profile and provide excellent hemodynamic relief of aortic stenosis. The Edwards Sapien valve is currently under investigation in the United States in the PARTNER (Placement of Aortic Transcatheter Valve) trial in high-risk surgical or inoperable patients; TAVI is available for clinical use in both Canada and Europe. TAVI is not used in low- or intermediate-risk surgical patients; however, future studies may prove its applicability in these subsets. The major complications of TAVI include access site-related problems and device malpositioning/migration. There are several new-generation prosthetic valves and delivery systems designed to be low profile and repositionable. Technical advances and refinement of the implantation methods may make TAVI even safer and ultimately a better treatment option, not only for patients with high surgical risk but also for those with moderate or low risk.
Similar content being viewed by others
References and Recommended Reading
Bonow RO, Carabello BA, Chatterjee K, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52:e1–e142.
Iung B, Baron G, Butchart EG, et al.: A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003, 24:1231–1243.
Nkomo VT, Gardin JM, Skelton TN, et al.: Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005–1011.
Lindroos M, Kupari M, Heikkila J, Tilvis R: Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993, 21:1220–1225.
American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al.: ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006, 114:e84–e231.
Horstkotte D, Loogen F: The natural history of aortic valve stenosis. Eur Heart J 1988, 9(Suppl E):57–64.
Iivanainen AM, Lindroos M, Tilvis R, et al.: Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol 1996, 78:97–101.
Chizner MA, Pearle DL, deLeon AC Jr: The natural history of aortic stenosis in adults. Am Heart J 1980, 99:419–424.
Varadarajan P, Kapoor N, Bansal RC, Pai RG: Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006, 82:2111–2115.
Iung B, Cachier A, Baron G, et al.: Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005, 26:2714–2720.
Bouma BJ, van Den Brink RB, van Der Meulen JH, et al.: To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 1999, 82:143–148.
Pai RG, Kapoor N, Bansal RC, Varadarajan P: Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg 2006, 82:2116–2122.
Bach DS, Cimino N, Deeb GM: Unoperated patients with severe aortic stenosis. J Am Coll Cardiol 2007, 50:2018–2019.
Cribier A, Eltchaninoff H, Tron C, et al.: Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006, 47:1214–1223.
Grube E, Laborde JC, Gerckens U, et al.: Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006, 114:1616–1624.
Webb JG, Chandavimol M, Thompson CR, et al.: Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006, 113:842–850.
Vassiliades TA Jr, Block PC, Cohn LH, et al.: The clinical development of percutaneous heart valve technology. J Thorac Cardiovasc Surg 2005, 129:970–976.
Walther T, Simon P, Dewey T, et al.: Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 2007, 116(11 Suppl):I240–I245.
Block PC, Bonhoeffer P: Percutaneous approaches to valvular heart disease. Curr Cardiol Rep 2005, 7:108–113.
Zajarias A, Cribier AG: Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009, 53:1829–1836.
Webb JG, Altwegg L, Boone RH, et al.: Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009, 119:3009–3016.
Andersen HR, Knudsen LL, Hasenkam JM: Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J 1992, 13:704–708.
Webb JG, Altwegg L, Masson JB, et al.: A new transcatheter aortic valve and percutaneous valve delivery system. J Am Coll Cardiol 2009, 53:1855–1858.
Webb JG, Pasupati S, Humphries K, et al.: Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007, 116:755–763.
Lichtenstein SV, Cheung A, Ye J, et al.: Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation 2006, 114:591–596.
Ye J, Cheung A, Lichtenstein SV, et al.: Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. Eur J Cardiothorac Surg 2007, 31:16–21.
Walther T, Falk V, Borger MA, et al.: Minimally invasive transapical beating heart aortic valve implantation—proof of concept. Eur J Cardiothorac Surg 2007, 31:9–15.
Svensson LG, Dewey T, Kapadia S, et al.: United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg 2008, 86:46–54; discussion 55.
Grube E, Laborde JC, Zickmann B, et al.: First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv 2005, 66:465–469.
Grube E, Schuler G, Buellesfeld L, et al.: Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 2007, 50:69–76.
Kapadia SR, Svensson L, Tuzcu EM: Successful percutaneous management of left main trunk occlusion during percutaneous aortic valve replacement. Catheter Cardiovasc Interv 2009, 73:966–972.
Kodali S: Edward’s valve experience. Presented at the 20th Annual Transcatheter Cardiovascular Therapeutics Meeting. Washington, DC; October 12–17, 2008.
Webb JG: Vancouver experience. Presented at the 20th Annual Transcatheter Cardiovascular Therapeutics Meeting. Washington, DC; October 12–17, 2008.
Lefevre T: European experience with balloon expandable valve. Presented at the 20th Annual Transcatheter Cardiovascular Therapeutics Meeting. Washington, DC; October 12–17, 2008.
Grube E, Buellesfeld L, Mueller R, et al.: Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve revalving system. Circ Cardiovasc Interv 2008, 1:167–175.
Bleiziffer S, Ruge H, Mazzitelli D, et al.: Results of percutaneous and transapical transcatheter aortic valve implantation performed by a surgical team. Eur J Cardiothorac Surg 2009, 35:615–620; discussion 620–621.
Tamburino C, Capodanno D, Mul EM, et al.: Procedural success and 30-day clinical outcomes after percutaneous aortic valve replacement using current third-generation self-expanding CoreValve prosthesis. J Invasive Cardiol 2009, 21:93–98.
Laborde JC: CoreValve experience. Presented at the 58th Annual Meeting of the American College of Cardiology. Orlando, FL; March 29–31, 2009.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapadia, S.R., Murat Tuzcu, E. Transcatheter aortic valve implantation. Curr Treat Options Cardio Med 11, 467–475 (2009). https://doi.org/10.1007/s11936-009-0049-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11936-009-0049-x